Global RNA Based Therapies Market - 2025 -2033
Global RNA-based Therapies Market: Industry Outlook
The global RNA-based therapies market was values as US$90.56 billion in 2024, and is expected to reach US$ 213.54billionby 2033, growing at a CAGR of 10.0% during the forecast period 2025-2033.
The global RNA-based therapeutics market is growing due to advancements in delivery technologies, personalized medicine, and the rise of rare genetic disorders, cancers, and infectious diseases. Collaborations between pharmaceutical and biotechnology companies and investment in RNA research are driving growth. Commercial success of mRNA vaccines has boosted confidence in RNA modalities, leading to faster clinical development and broader therapeutic applications. However, challenges include high development costs, scalability issues, regulatory complexities, safety concerns, and competition from other treatment approaches. Opportunities are expanding in areas like oncology, cardiometabolic disorders, immunology, and rare diseases, supported by innovations like self-amplifying RNA and small activating RNA.
Drivers & Restraints
Driver: Rising Prevalence of Genetic and Rare Diseases
The increasing prevalence of genetic and rare diseases is driving the RNA-based therapeutics market, as these conditions often lack effective treatments and are caused by well-defined genetic mutations. RNA technologies, such as antisense oligonucleotides, small interfering RNAs, and messenger RNAs, can modulate or replace specific gene expressions, making them ideal for rare, inherited, and orphan diseases. Global awareness, improved genetic screening, and supportive regulatory frameworks are incentivizing research and development in this area. As more rare disease patients receive accurate diagnoses, demand for precision therapies is increasing, positioning RNA-based therapeutics as a transformative solution.
For instance, rare diseases affect a small number of individuals, but with over 7000 types, the global burden is significant. Approximately 300 million people live with rare diseases, often neglected and marginalized, particularly in low-income and middle-income countries.
Restraint: Complex Regulatory Pathways and Safety Concerns
The RNA-based therapeutics market faces challenges due to complex regulatory pathways and safety concerns. Regulatory agencies require extensive preclinical and clinical data to assess risks like off-target effects, immune system activation, toxicity, and potential gene modulation. This often extends development timelines and increases costs.
The novelty of some RNA platforms means limited long-term safety data, prompting cautious review by authorities and conservative prescribing by clinicians. This combination of rigorous oversight, evolving compliance requirements, and safety verification can slow product launches, deter smaller companies, and affect investor confidence, despite the science's progress.
Segmentation Analysis
The global RNA-based therapies market is segmented based on type, indication, end user, and region.
Type: The Antisense Oligonucleotides (ASO)from the type segment the expected to have 25.51% of the RNA-based Therapies market share.
The Antisense Oligonucleotides (ASO) segment is gaining popularity in the RNA-based therapeutics market due to its ability to target specific genetic mutations causing rare and untreatable diseases. ASOs offer high specificity by binding to complementary RNA sequences, allowing precise gene expression modulation. Breakthrough therapies like nusinersen and eteplirsen have demonstrated clinical efficacy and regulatory and commercial viability, encouraging further investment and pipeline expansion. Advances in backbone chemistry and delivery systems are enhancing ASO stability, tissue penetration, and safety profiles, allowing systemic administration and targeting difficult-to-reach tissues.
For instance, in November 2024, Trace Neuroscience, founded in January, raised $101 million in a series A financing round to advance its antisense oligonucleotide therapy (ASO) treatment for ALS, a condition gained awareness through the ice-bucket challenge.
Geographical Analysis
The North America global RNA-based therapies market was valued at 42.1% market share in 2024
North America's RNA-based therapeutics market is thriving due to advanced research infrastructure, robust funding, and a supportive regulatory environment. The region's RNA-focused biopharmaceutical companies, partnership with companies, academic research centers, and specialized manufacturing facilities create a robust pipeline for drug development. High adoption of genetic testing and precision medicine, along with well-established reimbursement frameworks for rare and orphan disease treatments, is fostering rapid market uptake.
For instance, in May 2025, Eli Lilly and South Korean biopharmaceutical company Rznomics have partnered to develop and commercialize novel RNA-editing therapies for sensorineural hearing loss, using Rznomics' proprietary trans-splicing ribozyme platform, a clinical-stage biopharmaceutical company.
Market –Major Players
The major players in the RNA-based Therapies market include Sarepta Therapeutics, Alnylam Pharmaceuticals, NS Pharma, Pfizer, Modern Therapeutics, Novartis, Biogen, and Novo Nordisk among others.
Key Developments
The global RNA-based therapies market was values as US$90.56 billion in 2024, and is expected to reach US$ 213.54billionby 2033, growing at a CAGR of 10.0% during the forecast period 2025-2033.
The global RNA-based therapeutics market is growing due to advancements in delivery technologies, personalized medicine, and the rise of rare genetic disorders, cancers, and infectious diseases. Collaborations between pharmaceutical and biotechnology companies and investment in RNA research are driving growth. Commercial success of mRNA vaccines has boosted confidence in RNA modalities, leading to faster clinical development and broader therapeutic applications. However, challenges include high development costs, scalability issues, regulatory complexities, safety concerns, and competition from other treatment approaches. Opportunities are expanding in areas like oncology, cardiometabolic disorders, immunology, and rare diseases, supported by innovations like self-amplifying RNA and small activating RNA.
Drivers & Restraints
Driver: Rising Prevalence of Genetic and Rare Diseases
The increasing prevalence of genetic and rare diseases is driving the RNA-based therapeutics market, as these conditions often lack effective treatments and are caused by well-defined genetic mutations. RNA technologies, such as antisense oligonucleotides, small interfering RNAs, and messenger RNAs, can modulate or replace specific gene expressions, making them ideal for rare, inherited, and orphan diseases. Global awareness, improved genetic screening, and supportive regulatory frameworks are incentivizing research and development in this area. As more rare disease patients receive accurate diagnoses, demand for precision therapies is increasing, positioning RNA-based therapeutics as a transformative solution.
For instance, rare diseases affect a small number of individuals, but with over 7000 types, the global burden is significant. Approximately 300 million people live with rare diseases, often neglected and marginalized, particularly in low-income and middle-income countries.
Restraint: Complex Regulatory Pathways and Safety Concerns
The RNA-based therapeutics market faces challenges due to complex regulatory pathways and safety concerns. Regulatory agencies require extensive preclinical and clinical data to assess risks like off-target effects, immune system activation, toxicity, and potential gene modulation. This often extends development timelines and increases costs.
The novelty of some RNA platforms means limited long-term safety data, prompting cautious review by authorities and conservative prescribing by clinicians. This combination of rigorous oversight, evolving compliance requirements, and safety verification can slow product launches, deter smaller companies, and affect investor confidence, despite the science's progress.
Segmentation Analysis
The global RNA-based therapies market is segmented based on type, indication, end user, and region.
Type: The Antisense Oligonucleotides (ASO)from the type segment the expected to have 25.51% of the RNA-based Therapies market share.
The Antisense Oligonucleotides (ASO) segment is gaining popularity in the RNA-based therapeutics market due to its ability to target specific genetic mutations causing rare and untreatable diseases. ASOs offer high specificity by binding to complementary RNA sequences, allowing precise gene expression modulation. Breakthrough therapies like nusinersen and eteplirsen have demonstrated clinical efficacy and regulatory and commercial viability, encouraging further investment and pipeline expansion. Advances in backbone chemistry and delivery systems are enhancing ASO stability, tissue penetration, and safety profiles, allowing systemic administration and targeting difficult-to-reach tissues.
For instance, in November 2024, Trace Neuroscience, founded in January, raised $101 million in a series A financing round to advance its antisense oligonucleotide therapy (ASO) treatment for ALS, a condition gained awareness through the ice-bucket challenge.
Geographical Analysis
The North America global RNA-based therapies market was valued at 42.1% market share in 2024
North America's RNA-based therapeutics market is thriving due to advanced research infrastructure, robust funding, and a supportive regulatory environment. The region's RNA-focused biopharmaceutical companies, partnership with companies, academic research centers, and specialized manufacturing facilities create a robust pipeline for drug development. High adoption of genetic testing and precision medicine, along with well-established reimbursement frameworks for rare and orphan disease treatments, is fostering rapid market uptake.
For instance, in May 2025, Eli Lilly and South Korean biopharmaceutical company Rznomics have partnered to develop and commercialize novel RNA-editing therapies for sensorineural hearing loss, using Rznomics' proprietary trans-splicing ribozyme platform, a clinical-stage biopharmaceutical company.
Market –Major Players
The major players in the RNA-based Therapies market include Sarepta Therapeutics, Alnylam Pharmaceuticals, NS Pharma, Pfizer, Modern Therapeutics, Novartis, Biogen, and Novo Nordisk among others.
Key Developments
- In January 2025, Danish biotech company nverna Therapeutics, co-founded by the University of Southern Denmark and Argobio, has launched as a leading-edge RNA therapeutics company. The company aims to improve patient outcomes in severe genetic diseases, starting with a program addressing Huntington's disease.
- In September 2024, Aurora Biosynthetic, a leading RNA therapeutics manufacturing company, has launched its new end-to-end solution for Good Manufacturing Practice (GMP) production of plasmid DNA, messenger RNA, and lipid nanoparticles, marking a new era in RNA therapeutics manufacturing in the Asia-Pacific region.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Indication
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Genetic and Rare Diseases
3.1.1.2. Technological Advancements in Delivery Systems
3.1.2. Restraints
3.1.2.1. Complex Regulatory Pathways and Safety Concerns
3.1.2.2. Delivery and Stability Challenges
3.1.3. Opportunity
3.1.3.1. Precision Medicine & Personalized Therapies
3.1.3.2. Rise in Strategic Acquisitions & Collaborations
3.1.4. Impact Analysis
4. GLOBAL RNA-BASED THERAPIES MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products& Services
4.2. Product Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL RNA-BASED THERAPIES MARKET: BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Antisense Oligonucleotides (ASO)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. RNA interference
5.4. CRISPR/Cas-based RNA editing system
5.5. mRNA vaccines
5.6. RNA Aptamers
5.7. Others
6. GLOBAL RNA-BASED THERAPIES MARKET: BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Rare Genetic Diseases*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Rare Genetic Diseases
6.4. Oncology
6.5. Infectious Diseases
6.6. Neuromuscular
6.7. Others
7. GLOBAL RNA-BASED THERAPIES MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals& Clinics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Research Institutes
7.4. Pharmaceutical & Biotech Companies
8. GLOBAL RNA-BASED THERAPIES MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Ionis Pharmaceuticals*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Sarepta Therapeutics
10.3. Alnylam Pharmaceuticals
10.4. NS Pharma
10.5. Pfizer
10.6. Moderna Therapeutics
10.7. Novartis
10.8. Biogen
10.9. Novo Nordisk (LIST NOT EXHAUSTIVE )
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Indication
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Genetic and Rare Diseases
3.1.1.2. Technological Advancements in Delivery Systems
3.1.2. Restraints
3.1.2.1. Complex Regulatory Pathways and Safety Concerns
3.1.2.2. Delivery and Stability Challenges
3.1.3. Opportunity
3.1.3.1. Precision Medicine & Personalized Therapies
3.1.3.2. Rise in Strategic Acquisitions & Collaborations
3.1.4. Impact Analysis
4. GLOBAL RNA-BASED THERAPIES MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products& Services
4.2. Product Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL RNA-BASED THERAPIES MARKET: BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Antisense Oligonucleotides (ASO)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. RNA interference
5.4. CRISPR/Cas-based RNA editing system
5.5. mRNA vaccines
5.6. RNA Aptamers
5.7. Others
6. GLOBAL RNA-BASED THERAPIES MARKET: BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Rare Genetic Diseases*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Rare Genetic Diseases
6.4. Oncology
6.5. Infectious Diseases
6.6. Neuromuscular
6.7. Others
7. GLOBAL RNA-BASED THERAPIES MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals& Clinics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Research Institutes
7.4. Pharmaceutical & Biotech Companies
8. GLOBAL RNA-BASED THERAPIES MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Ionis Pharmaceuticals*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Sarepta Therapeutics
10.3. Alnylam Pharmaceuticals
10.4. NS Pharma
10.5. Pfizer
10.6. Moderna Therapeutics
10.7. Novartis
10.8. Biogen
10.9. Novo Nordisk (LIST NOT EXHAUSTIVE )
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global RNA-based Therapies Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global RNA-based Therapies Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global RNA-based Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global RNA-based Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global RNA-based Therapies Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 7 Global RNA-based Therapies Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global RNA-based Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 11 Global RNA-based Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global RNA-based Therapies Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 North America RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 16 North America RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 18 Europe RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 Europe RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 South America RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 28 South America RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Ionis Pharmaceuticals: Overview
Table 34 Ionis Pharmaceuticals: Product Portfolio
Table 35 Ionis Pharmaceuticals: Key Developments
Table 36 Sarepta Therapeutics: Overview
Table 37 Sarepta Therapeutics: Product Portfolio
Table 38 Sarepta Therapeutics: Key Developments
Table 39 Alnylam Pharmaceuticals: Overview
Table 40 Alnylam Pharmaceuticals: Product Portfolio
Table 41 Alnylam Pharmaceuticals: Key Developments
Table 42 NS Pharma: Overview
Table 43 NS Pharma: Product Portfolio
Table 44 NS Pharma: Key Developments
Table 45 Pfizer: Overview
Table 46 Pfizer: Product Portfolio
Table 47 Pfizer: Key Developments
Table 48 Moderna Therapeutics: Overview
Table 49 Moderna Therapeutics: Product Portfolio
Table 50 Moderna Therapeutics: Key Developments
Table 51 Novartis: Overview
Table 52 Novartis: Product Portfolio
Table 53 Novartis: Key Developments
Table 54 Biogen: Overview
Table 55 Biogen: Product Portfolio
Table 56 Biogen: Key Developments
Table 57 Novo Nordisk: Overview
Table 58 Novo Nordisk: Product Portfolio
Table 59 Novo Nordisk: Key Developments
Table 1 Global RNA-based Therapies Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global RNA-based Therapies Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global RNA-based Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global RNA-based Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global RNA-based Therapies Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 7 Global RNA-based Therapies Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global RNA-based Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 11 Global RNA-based Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global RNA-based Therapies Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 North America RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 16 North America RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 18 Europe RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 Europe RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 South America RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 28 South America RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa RNA-based Therapies Market Value, By Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa RNA-based Therapies Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa RNA-based Therapies Market Value, By End User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa RNA-based Therapies Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Ionis Pharmaceuticals: Overview
Table 34 Ionis Pharmaceuticals: Product Portfolio
Table 35 Ionis Pharmaceuticals: Key Developments
Table 36 Sarepta Therapeutics: Overview
Table 37 Sarepta Therapeutics: Product Portfolio
Table 38 Sarepta Therapeutics: Key Developments
Table 39 Alnylam Pharmaceuticals: Overview
Table 40 Alnylam Pharmaceuticals: Product Portfolio
Table 41 Alnylam Pharmaceuticals: Key Developments
Table 42 NS Pharma: Overview
Table 43 NS Pharma: Product Portfolio
Table 44 NS Pharma: Key Developments
Table 45 Pfizer: Overview
Table 46 Pfizer: Product Portfolio
Table 47 Pfizer: Key Developments
Table 48 Moderna Therapeutics: Overview
Table 49 Moderna Therapeutics: Product Portfolio
Table 50 Moderna Therapeutics: Key Developments
Table 51 Novartis: Overview
Table 52 Novartis: Product Portfolio
Table 53 Novartis: Key Developments
Table 54 Biogen: Overview
Table 55 Biogen: Product Portfolio
Table 56 Biogen: Key Developments
Table 57 Novo Nordisk: Overview
Table 58 Novo Nordisk: Product Portfolio
Table 59 Novo Nordisk: Key Developments
LIST OF FIGURES
Figure 1 Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 2 Global RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 5 Global RNA-based Therapies Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global RNA-based Therapies Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 7 Antisense Oligonucleotides (ASO) RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 8 RNA interference RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 9 CRISPR/Cas-based RNA editing system RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 10 mRNA vaccines RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 11 RNA Aptamers RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 12 Others RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 13 Global RNA-based Therapies Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 14 Rare Genetic Diseases Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 15 Oncology Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 16 Infectious Diseases Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 17 Neuromuscular Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 19 Global RNA-based Therapies Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 20 Hospitals & Clinics End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 21 Research Institutes End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 22 Pharmaceutical & Biotech Companies End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 23 Global RNA-based Therapies Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 24 North America RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 25 North America RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 26 North America RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 27 North America RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 28 North America RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 31 Europe RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 32 Europe RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 33 Europe RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 34 Asia-Pacific RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 35 Asia-Pacific RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 37 Asia-Pacific RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 38 Asia-Pacific RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 39 South America RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 40 South America RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 41 South America RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 42 South America RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 43 South America RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 45 Middle East and Africa RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 47 Middle East and Africa RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 48 Ionis Pharmaceuticals: Financials
Figure 49 Sarepta Therapeutics: Financials
Figure 50 Alnylam Pharmaceuticals: Financials
Figure 51 NS Pharma: Financials
Figure 52 Pfizer: Financials
Figure 53 Moderna Therapeutics: Financials
Figure 54 Novartis: Financials
Figure 55 Biogen: Financials
Figure 56 Novo Nordisk: Financials
Figure 1 Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 2 Global RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 5 Global RNA-based Therapies Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global RNA-based Therapies Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 7 Antisense Oligonucleotides (ASO) RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 8 RNA interference RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 9 CRISPR/Cas-based RNA editing system RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 10 mRNA vaccines RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 11 RNA Aptamers RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 12 Others RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 13 Global RNA-based Therapies Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 14 Rare Genetic Diseases Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 15 Oncology Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 16 Infectious Diseases Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 17 Neuromuscular Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Indication in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 19 Global RNA-based Therapies Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 20 Hospitals & Clinics End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 21 Research Institutes End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 22 Pharmaceutical & Biotech Companies End User in Global RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 23 Global RNA-based Therapies Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 24 North America RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 25 North America RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 26 North America RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 27 North America RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 28 North America RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 31 Europe RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 32 Europe RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 33 Europe RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 34 Asia-Pacific RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 35 Asia-Pacific RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 37 Asia-Pacific RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 38 Asia-Pacific RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 39 South America RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 40 South America RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 41 South America RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 42 South America RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 43 South America RNA-based Therapies Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa RNA-based Therapies Market Value, 2022-2033 (US$ Billion)
Figure 45 Middle East and Africa RNA-based Therapies Market Share, By Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa RNA-based Therapies Market Share, By Indication, 2024 & 2033 (%)
Figure 47 Middle East and Africa RNA-based Therapies Market Share, By End User, 2024 & 2033 (%)
Figure 48 Ionis Pharmaceuticals: Financials
Figure 49 Sarepta Therapeutics: Financials
Figure 50 Alnylam Pharmaceuticals: Financials
Figure 51 NS Pharma: Financials
Figure 52 Pfizer: Financials
Figure 53 Moderna Therapeutics: Financials
Figure 54 Novartis: Financials
Figure 55 Biogen: Financials
Figure 56 Novo Nordisk: Financials
